Loading
A phase 1 trial of SENTI-202 run by Senti Biosciences, active and no longer recruiting.
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS is a phase 1 interventional study registered as NCT06325748 by Senti Biosciences, with 21 participants planned, started 2024-04-22. Conditions recorded: AML/MDS, CD33 Expressing Hematological Malignancies and FLT3 Expressing Hematological Malignancies. Interventions recorded: SENTI-202.
Shares Acute myeloid leukaemia, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Acute myeloid leukaemia, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Acute myeloid leukaemia, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/